Equities analysts expect that Repligen Co. (NASDAQ:RGEN) will post $0.21 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Repligen’s earnings, with the lowest EPS estimate coming in at $0.20 and the highest estimate coming in at $0.22. Repligen posted earnings per share of $0.20 in the same quarter last year, which suggests a positive year over year growth rate of 5%. The company is expected to issue its next quarterly earnings results on Thursday, February 28th.
According to Zacks, analysts expect that Repligen will report full-year earnings of $0.73 per share for the current fiscal year, with EPS estimates ranging from $0.71 to $0.74. For the next fiscal year, analysts anticipate that the business will post earnings of $0.85 per share, with EPS estimates ranging from $0.82 to $0.92. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Repligen.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, November 1st. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The business had revenue of $49.53 million for the quarter, compared to the consensus estimate of $46.69 million. Repligen had a return on equity of 5.39% and a net margin of 12.61%. The business’s quarterly revenue was up 35.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.15 earnings per share.
A number of equities research analysts have recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of Repligen in a report on Friday, November 2nd. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating in a report on Wednesday. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 16th. Citigroup boosted their price objective on shares of Repligen from $45.00 to $56.00 and gave the company a “buy” rating in a report on Friday, July 20th. Finally, Stephens boosted their price objective on shares of Repligen from $50.00 to $55.00 and gave the company an “average” rating in a report on Tuesday, July 10th. Three analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $59.33.
In other news, CFO Jon Snodgres sold 14,460 shares of the stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $52.79, for a total transaction of $763,343.40. Following the sale, the chief financial officer now directly owns 20,899 shares of the company’s stock, valued at approximately $1,103,258.21. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Thomas F. Ryan, Jr. sold 2,366 shares of the stock in a transaction dated Wednesday, August 22nd. The stock was sold at an average price of $51.44, for a total transaction of $121,707.04. Following the sale, the director now directly owns 4,988 shares in the company, valued at $256,582.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 52,735 shares of company stock worth $2,950,017. 1.40% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in shares of Repligen by 9.1% during the 2nd quarter. BlackRock Inc. now owns 5,851,161 shares of the biotechnology company’s stock worth $275,239,000 after acquiring an additional 485,777 shares in the last quarter. OppenheimerFunds Inc. raised its position in shares of Repligen by 7.4% during the 2nd quarter. OppenheimerFunds Inc. now owns 2,135,929 shares of the biotechnology company’s stock worth $100,473,000 after purchasing an additional 146,290 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in shares of Repligen by 13.4% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,941,212 shares of the biotechnology company’s stock worth $107,660,000 after purchasing an additional 230,080 shares during the last quarter. Macquarie Group Ltd. raised its position in shares of Repligen by 12.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,107,691 shares of the biotechnology company’s stock worth $52,106,000 after purchasing an additional 121,157 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Repligen by 0.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,016,820 shares of the biotechnology company’s stock worth $47,831,000 after purchasing an additional 3,489 shares during the last quarter. 93.08% of the stock is currently owned by institutional investors and hedge funds.
Shares of RGEN traded up $1.85 during trading hours on Friday, reaching $69.76. 39,341 shares of the company traded hands, compared to its average volume of 523,591. The firm has a market capitalization of $2.90 billion, a PE ratio of 101.19, a price-to-earnings-growth ratio of 5.22 and a beta of 0.74. Repligen has a 12-month low of $29.56 and a 12-month high of $68.50.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process worldwide. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Featured Story: Short Selling – Explanation For Shorting Stocks
Get a free copy of the Zacks research report on Repligen (RGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.